This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Alberta directory, so their publications, courses and email address may be missing. Find their university profile.
Latest funding
- $722,926
Nimodipine Systemic Exposure and Outcomes Following Aneurysmal Subarachnoid Hemorrhage: A Prospective Multicenter Observational Study (ASH-II Study)
CIHR · 2024 · Nominated PI
- $100,000
Nimodipine Systemic Exposure and Outcomes Following Aneurysmal Subarachnoid Hemorrhage: A Prospective Multi-centre Observational Study (ASH-II Study)
CIHR · 2023 · Nominated PI
- $730,576
FOXM1 protein-targeted degradation and its potential role in the treatment of ovarian cancer: a medicinal chemistry approach
CIHR · 2022 · Co-investigator
Nimodipine Systemic Exposure and Outcomes Following Aneurysmal Subarachnoid Hemorrhage: A Prospective Multicenter Observational Study (ASH-II Study)
Principal investigators: Mahmoud, Sherif H
Keywords: Chiral Compound; Nimodipine; Pharmacokinetics; Subarachnoid Hemorrhage
Nimodipine Systemic Exposure and Outcomes Following Aneurysmal Subarachnoid Hemorrhage: A Prospective Multi-centre Observational Study (ASH-II Study)
Principal investigators: Mahmoud, Sherif H
Keywords: Chiral Compound; Nimodipine; Pharmacokinetics; Subarachnoid Hemorrhage
FOXM1 protein-targeted degradation and its potential role in the treatment of ovarian cancer: a medicinal chemistry approach
Principal investigators: Velazquez, Carlos A
Keywords: Drug Design; Forkhead Box Proteins; Foxm1; Medicinal Chemistry; Molecular Modeling; Ovarian Cancer; Transcription; Transcription Factors
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.